ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 15, 2017Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific subgroup of the trial’s patient population – a subgroup which the Swiss drugmaker is now looking to target with the
Pharma Sources Insight January 2025
